

PAR/CS/NSE/2026-27/12

To,
The Manager
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400 051
Maharashtra

Date:10/08/2026

Subject: Submission of Newspapers Cutting of published Standalone Unaudited Financial Results for the quarter ended June 30, 2026

Ref.: **Symbol- PAR, ISIN: INE04LG01015**

Dear Sir/Madam,

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the cuttings of newspaper advertisement published in Newspaper dated August 10, 2026 in The Economic Times (English) and Navgujarat Samay (Gujarati), regarding Standalone Unaudited Financial Results for the quarter ended June 30, 2026.

Copies of newspapers cutting in this connection are attached herewith.

The above information is also available on the website of the Company www.pardrugs.com

Kindly take on the record and acknowledge the receipt

Yours Faithfully

For PAR DRUGS AND CHEMICALS LIMITED

(Sanket B. Trivedi)**Company Secretary & Compliance Officer**

Global Banks Reluctant to Sell Cards to Wealthy Indians

Sugata Ghosh

Mumbai: For years, many rich Indians have revelled in the hushed convenience of international credit cards from offshore banks—unlimited spends, no currency conversion charges, and, more importantly, income tax and enforcement departments not automatically coming to know where and how money was spent abroad. That's becoming a problem now.

Several offshore banks in Zurich, Singapore, London and even parts of West Asia—usual centres for operating investment and chequeable accounts—are refusing to issue cards to wealthy Indians. Not that credit scores of such clients have plunged, but simply because an Indian rule forbids resident Indians to have idle money lying in foreign accounts beyond six months, multiple persons told ET.

Cards that expired or are coming up for renewal, are impacted by this 2022 regulation introduced when Reserve Bank of India (RBI) overhauled overseas investment norms, including Liberalised Remittance Scheme (LRS)—the window for residents to legitimately invest and spend up to \$250,000 a year abroad.

"An unintended consequence of the 180-day deployment requirement under LRS is beginning to show up in overseas banking relationships of Indian families. Residents have limited flexibility to retain meaningful balances overseas, making some international banks reluctant to offer credit cards linked to these accounts, even though regulations recognise use of such cards," said Moin Ladha, partner at law firm Khaitan & Co.

Under 'redemption', a resident must spend or invest within 180 days the LRS amount remitted or bring back unused funds. Holding unspent money in checking account (like savings account) or as fixed deposits with foreign banks don't qualify as deployment which stand for buying securities and properties or undertaking permitted current account transactions like booking hotels, purchasing air tickets, and settling restaurant bills.

"Resident individuals and returning Indians often hold foreign-issued international credit cards (ICCs) which are operationally efficient as expenditure is incurred in the same currency, thereby eliminating conversion cost. Besides, under FEMA, there's no specific monetary ceiling fixed by RBI for remittances from India towards settlement of such foreign card liabilities, with the operative limit effectively being



Card Conundrum
Many HNIs opt for international credit cards from overseas banks

This is because of flexibility and lower cost

Offshore banks insist on large balances, FDs against such cards

Also, the re-deployment rule is also impacting minor foreign a/c under LRS

But residents can't keep idle balances, FDs under RBI 2022 rule

the credit limit sanctioned by foreign bank or card operator.

Technically, since settlement of such dues isn't treated as LRS remittance under RBI guidance, foreign-issued ICC spends may remain outside TCS, even after Indian banks operationalise TCS collection framework for forex spends incurred in India using ICCs issued in India," said Harshal Bhuta, partner at the CA firm PR Bhuta & Co. Under FATCA and other data-exchange pacts, foreign jurisdictions don't share ICC spend details with India.

MINOR ACCOUNTS, MAJOR CHALLENGES

Minors are particularly hit by the redemption challenge. "Minors are permitted to remit under LRS but have relatively limited avenues to appropriately deploy those funds, and overseas banks are increasingly questioning the continuation of such accounts."

Some calibrated flexibility in the 180-day requirement, particularly for minors, could address these practical challenges without diluting the broader regulatory intent of LRS framework," said Ladha.

Bibi Rejects US Gaza Plan, Vows No Pullout Until Hamas Disarms

Jerusalem | Cairo: Israeli Prime Minister Benjamin Netanyahu on Sunday reiterated his rejection of U.S. President Donald Trump's latest Gaza plan, even as Israel's military has largely halted attacks in the territory under pressure from Washington.

Netanyahu is in campaign mode ahead of an election due on Oct. 27 but is caught between far-right ministers opposed to concessions in Gaza and Trump, his key military backer, who is pushing for progress towards ending the conflict under a new 15-point peace plan.

Israel has scaled back attacks in

Gaza since Monday, when Nikolay Mladenov, the Gaza envoy for Trump's Board of Peace, which oversees the ceasefire, met with Netanyahu.

A source familiar with Israel's position said the government had agreed that the military would act only against what it considers immediate threats in Gaza and would no longer carry out targeted assassinations, as it had been doing almost daily.

Trump announced last month that his plan to end the war had reached a breakthrough, with Israel and Hamas agreeing to a framework under which Israeli

forces would withdraw as Hamas disarms and an International Stabilization Force works with a new Palestinian police force to secure the enclave.

But complications have quickly emerged. Israel has said its troops will not withdraw from Gaza before Hamas disarms, while Hamas has insisted that Israel halt attacks before it begins implementing the part of the agreement concerning its weapons. "Israel does not accept the 15-point document," Netanyahu said at the start of a meeting with cabinet ministers. — Reuters

Daiichi Sankyo Case HC Verdict Likely This Week

Teena Thacker

New Delhi: The Delhi High Court is expected to pronounce its judgment this week in the long-running Daiichi Sankyo arbitration case, after reserving the matter at the close of its 50th hearing in May.

Japanese drugmaker Daiichi Sankyo is seeking enforcement of an arbitration award in its favour against former Fortis

promoters Malvinder and Shivinder Mohan Singh for alleged fraud in the 2008 sale of their pharmaceutical company Ranbaxy Laboratories to the Japanese firm. Including interest, the amount awarded by a Singapore tribunal a decade ago has now swelled to \$500 crore.

To secure the payment, Daiichi sought to prevent the Singh brothers from diluting their Fortis stake, but lenders invoked and sold off the brothers' pledged shares to recover debt. The case has effectively become a three-way contest among the Singh brothers, lenders and Fortis over who bears responsibility for the shrinking assets of the Singh brothers.

Daiichi, represented by senior advocate Arvind Nigam and advocate Gauraj Subramaniam, questioned transactions involving Fortis' stake, including the sale of 186 million encumbered shares, terming them deliberate asset stripping.

"18.6 crore (186 million) shares were encumbered by financial institutions and

banks—disclosures made, uploaded by the company and sold, leaving 13.99 crore shares, which were unencumbered and sold in transactions with the approval of the compliance officer at a point in time when FHL was an entity of the judgment debtors," Nigam argued before the bench of Justice Subramaniam Prasad.

During the last hearing, Fortis' counsel said that "FHL and its compliance officer never gave any approval to any of these transfers".



Par
DRUGS AND CHEMICALS LIMITED

Par Drugs And Chemicals Limited
CIN: L24117GJ1999PLC035512
Registered office: 815, Nilamber Triumph, Gotri Vasna Road, Vadodara-390007, Gujarat, India
Phone no.: 0265-2991021, 0265-2991022
Website: www.pardrugs.com Email: investors@pardrugs.com

Statement of Standalone Un-Audited Financial Result for the Quarter Ended June 30th, 2026

(Rs. in Lakh except per share data)

Sl. No.	Particulars	Quarter Ending			Year to date	
		30.06.2026	31.03.2026	30.06.2025	30.06.2026	31.03.2026
		Unaudited	Audited	Unaudited	Unaudited	Audited
1	Total Income from Operations	3,128.05	1,961.08	2,604.64	3,128.05	10,365.56
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	633.01	83.15	447.77	633.01	1,730.16
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items#)	633.01	83.15	447.77	633.01	1,730.16
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	471.27	85.36	332.80	471.27	1,310.86
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	471.27	85.36	332.80	471.27	1,310.86
6	Equity Share Capital (Face Value per share Rs. 10/-)	1,230.46	1,230.46	1,230.46	1,230.46	1,230.46
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	---	---	---	---	9,968.00
8	Earnings Per Share of Rs. 10/- Each (for continuing and discontinued operations) Basic as well as Diluted	3.83	0.69	2.70	3.83	10.65

Note: (a) The result have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on 08/08/2026. (b) The above is an extract of the detailed format of Statement of Unaudited standalone Financial Result for the Quarter ended June 30, 2026 filed with the National Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarter ended June 30, 2026 are available on the website viz <https://www.nseindia.com/> and the website of the Company at www.pardrugs.com (c) #Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable. (d) The Company is primarily engaged in manufacturing of API, which constitute single business segment in terms of Ind AS - 108 on "Operating Segments". Accordingly, there is no separate reportable segments as per Ind AS - 108. (e) The Company does not have any subsidiary, associates or joint venture as on June 30, 2026; therefore, it has prepared only standalone results as consolidation requirement is not applicable to the Company.

Date: 08/08/2026
Place: Vadodara



For & on Behalf of the Board
Par Drugs And Chemicals Limited
Sd/-
(Mr. Faigun V. Savani)
Managing Director
DIN: 00198236



GOLDIAM INTERNATIONAL LIMITED

GEMS & JEWELLERY COMPLEX, SEEPZ, ANDHERI (EAST), MUMBAI – 400 096.
CIN: L36912MH1986PLC041203 | Tel.: (022) 28291893 | Fax: (022) 28290418
investorrelations@goldiam.com | www.goldiam.com

EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

(₹ in Lakhs, except EPS)

Particulars	3 Months Ended 30-Jun-2026 (Unaudited)	3 Months Ended 31-Mar-2026 (Audited)	3 Months Ended 30-Jun-2025 (Unaudited)	Year Ended 31-Mar-2026 (Audited)
Total income from operations (net)	36,365.93	24,334.69	23,568.68	102,122.70
Net Profit / (Loss) before Tax, Exceptional and/or Extraordinary items	9,737.99	5,118.15	4,539.69	23,082.10
Net Profit / (Loss) after Tax, Exceptional and/or Extraordinary items	7,397.44	3,722.86	3,361.60	17,059.33
Total Comprehensive Income for the period	7,869.44	3,946.98	3,775.99	19,048.46
Net Profit / (Loss) after Taxes, including Minority Interest and Share of Profit / (Loss) of Associates	7,869.27	3,938.59	3,783.76	19,049.17
Paid-up Equity Share Capital (Face Value of ₹2/- per share)	2,258.35	2,258.35	2,135.90	2,258.35
Other Equity	-	-	-	108,344.01
Earnings Per Share (Not Annualised) – Basic	6.55	3.30	3.15	15.11
Earnings Per Share (Not Annualised) – Diluted	6.55	3.30	3.15	15.43

KEY HIGHLIGHTS – Q1 FY27

- PAT up 120% YoY to ₹74.0 crore
- Revenue up 54% YoY to ₹363.7 crore

The full format of the Unaudited result for the Quarter ended Jun, 30 2026 are available on the Stock Exchanges websites www.besindia.com, www.nesindia.com and on the website of the Company's at www.goldiam.com.



For Goldiam International Limited
Sd/-
Rashesh Bhansali
Executive Chairman

Place: Mumbai
Date: August 07, 2026





Comprehensive Income up by

↑ 6X

EBIT up by 3X at

6.6%↑

PBT up by 43X at

↑ ₹66 cr

EXTRACT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2026

(Rs. in Lakhs except per share data)

Sl. No.	PARTICULARS	QUARTER ENDED			YEAR ENDED
		30-JUN-26	31-MAR-26	30-JUN-25	31-MAR-26
		(UNAUDITED)	(AUDITED)	(UNAUDITED)	(AUDITED)
1	Total income from operations	1,11,498	1,24,895	1,09,493	4,52,434
2	Net profit / (loss) before tax	6,567	(5,194)	152	(8,898)
3	Net profit / (loss) after tax	4,838	(6,753)	91	(9,086)
4	Total comprehensive income	6,372	(9,311)	1,100	(10,744)
5	Equity Share Capital				2,308
6	Reserves (excluding Revaluation Reserve)				1,56,301
7	Networth				1,47,256
8	Earnings Per Share (not annualised) (Face value of Rs. 2/-)				
	Basic before exceptional items	3.54	(2.25)	0.51	(1.96)
	Diluted before exceptional items	3.53	(2.25)	0.51	(1.96)
	Basic after exceptional items	4.19	(5.85)	0.08	(7.88)
	Diluted after exceptional items	4.18	(5.85)	0.08	(7.88)

The above information has been extracted from the detailed consolidated unaudited financial results for the quarter ended 30th June 2026, which have been reviewed by the Audit Committee, approved by the Board of Directors and filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said financial results are available on the Stock Exchange websites, www.besindia.com and www.nesindia.com and on the Company's website www.bajajelectricals.com.

Place: Mumbai
Date: August 6, 2026

By order of the Board of Directors
for Bajaj Electricals Limited

Sheshkar Bajaj
Chairman

CIN : L31500MH1938PLC009887
Registered Office: Mulla House, 2nd Floor, 51, Mahatma Gandhi Road, Fort, Mumbai - 400001, Maharashtra, India
Tel. 022-61497000 Website : <http://www.bajajelectricals.com> Email : legal@bajajelectricals.com

